Vaxcyte, Inc. — Q1 2023 Form 10-Q
Business context and period: Unaudited results for the three months ended March 31, 2023, compared with Q1 2022. Vaxcyte is a clinical-stage vaccine developer with no approved products and no product-sales revenue. Its lead program is VAX-24, a 24-valent pneumococcal conjugate vaccine; VAX-31 is in preclinical development.
Key financial metrics
| Metric | Q1 2023 | Q1 2022 / prior date |
|---|---|---|
| Product revenue | None | None |
| Research and development expense | $58.1 million | $31.7 million |
| General and administrative expense | $13.1 million | $7.5 million |
| Total operating expenses / operating loss | $71.2 million | $39.2 million |
| Other income, net | $10.7 million | $0.2 million |
| Net loss | $60.5 million; $0.70 per share | $39.0 million; $0.68 per share |
| Net cash used in operating activities | $47.7 million | $27.7 million |
| Cash, cash equivalents and investments | $949.9 million at March 31, 2023 | $957.9 million at December 31, 2022 |
| Total assets / stockholders’ equity | $1,008.2 million / $944.8 million | $1,006.2 million / $953.6 million at December 31, 2022 |
Margins are not meaningful because the company had no product revenue. Vaxcyte reported no debt; it had $16.6 million of operating lease liabilities at quarter-end. Current assets were $840.7 million versus current liabilities of $52.7 million. The $448.1 million net investing cash outflow primarily reflects purchases of investments, rather than operating cash burn.
Material changes versus the prior comparable period
- Net loss increased $21.5 million, or 55.1%. Operating expenses rose 81.5%, driven chiefly by higher product and clinical development activity, including VAX-24 Phase 3 readiness and the start of the infant Phase 2 study, as well as increased headcount and stock compensation.
- R&D expense increased 83.3% to $58.1 million; G&A expense increased 73.8% to $13.1 million.
- Interest income rose to $10.4 million from $0.1 million, reflecting higher cash and investment balances and interest rates; this partly offset increased operating costs.
- Operating cash use increased to $47.7 million from $27.7 million. Financing cash provided was $41.6 million, mainly from ATM stock sales, compared with $111.0 million in Q1 2022, primarily from a public offering.
- Cash and cash equivalents fell from $834.7 million at year-end to $380.5 million, while investments increased from $123.3 million to $569.4 million, principally reflecting investment purchases and maturities.
Outlook, management commentary and risks
- Management said cash, cash equivalents and investments at March 31, 2023 were expected to fund operating expenses and capital requirements for at least 12 months from the filing date. It expects substantial future losses and expense growth as clinical, manufacturing and commercialization-readiness work advances; additional capital will be required to complete development and commercialization.
- VAX-24 adult studies had reported positive results before filing. The company planned FDA discussions in the second half of 2023 to inform the adult Phase 3 program, with Phase 3 topline data expected in 2025. The infant Phase 2 study began dosing in March 2023; topline results after the primary three-dose series were expected by 2025.
- VAX-31 adult IND submission and clearance were anticipated in the second half of 2023, with Phase 1/2 topline data expected in 2024. Timing remains subject to development, manufacturing and regulatory uncertainties.
- On April 21, 2023, after quarter-end, Vaxcyte completed an offering of common shares and pre-funded warrants, reporting $545.1 million of net proceeds, excluding exercise of the warrants. The filing also reports $145.1 million of non-cancelable manufacturing commitments due through 2024 and a $5.0 million Sutro payment commitment. The Sutro option, if exercised, could require $75.0 million plus up to $60.0 million in milestone payments.
- Key risks include clinical and regulatory failure or delay, possible FDA requirements for field efficacy studies, manufacturing scale-up and process challenges, and reliance on Lonza and other third parties, including single-source suppliers. Inflation, supply-chain disruption, foreign-exchange exposure and future financing needs are additional risks.
- The filing states that Vaxcyte recovered access to funds held at Silicon Valley Bank after its failure and reported no resulting losses. Management said disclosure controls and procedures were effective as of March 31, 2023; no material litigation was identified.
Important facts for investors to verify
- Progress and final, fully analyzed clinical results for VAX-24, including FDA alignment on Phase 3 design and whether additional efficacy studies will be required.
- Manufacturing readiness, capacity and continuity at Lonza and other suppliers, including fulfillment of the $145.1 million commitment schedule.
- Cash runway and spending trajectory in light of the April 2023 financing, ongoing clinical programs and possible Sutro option costs.
- Potential dilution from the April offering, pre-funded warrants, ATM program and equity compensation; the filing reports 93,706,790 common shares outstanding as of May 4, 2023.
- Whether clinical, regulatory, reimbursement and competitive developments support the stated timelines and commercial opportunity; the filing provides no product-revenue guidance.